[go: up one dir, main page]

WO1992007566A3 - Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues - Google Patents

Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues Download PDF

Info

Publication number
WO1992007566A3
WO1992007566A3 PCT/US1991/008086 US9108086W WO9207566A3 WO 1992007566 A3 WO1992007566 A3 WO 1992007566A3 US 9108086 W US9108086 W US 9108086W WO 9207566 A3 WO9207566 A3 WO 9207566A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
methylxanthine
4coh
analogues
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/008086
Other languages
French (fr)
Other versions
WO1992007566A2 (en
Inventor
David R Luke
Gabriel Lopez-Berestein
Kiumars Vadiei
Lane J Brunner
Kishor Wasan
Kurt L Berens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO1992007566A2 publication Critical patent/WO1992007566A2/en
Publication of WO1992007566A3 publication Critical patent/WO1992007566A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention involves the usage of certain hemorheological methylxanthine analogs having structure (I) where R1 is -(CH2)4COCH3, or -(CH2)4COH(CH3)2 and R2 is -CH3, -H or CH2OCH2CH3. These methylxanthine analogs may be used for treating a systemic fungal infection, for example candidiasis. Administration of the analogs, preferably by parenteral means, at least once and possibly on a multiple dosage schedule may be used to effectively ameliorate systemic fungal infections. The preferred therapeutically effective dosage for such treatment is between 1 mg and 100 mg per kg animal weight. A preferred analog for this treatment is when R1 is -(CH2)4COH(CH3)2 and R2 is -H. The above analogs may generally be used to treat an animal to inhibit developement of or to alleviate renal dysfunction manifested by reductions in renal blood flow and glomerular filtration rates with increased vascular resistance. This dysfunction may be independent or relate to the toxicity of other drugs such as cyclosporine or amphotericin B.
PCT/US1991/008086 1990-11-01 1991-11-01 Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues Ceased WO1992007566A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60815890A 1990-11-01 1990-11-01
US608,158 1990-11-01

Publications (2)

Publication Number Publication Date
WO1992007566A2 WO1992007566A2 (en) 1992-05-14
WO1992007566A3 true WO1992007566A3 (en) 1992-10-15

Family

ID=24435308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/008086 Ceased WO1992007566A2 (en) 1990-11-01 1991-11-01 Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues

Country Status (2)

Country Link
AU (1) AU9084991A (en)
WO (1) WO1992007566A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430127A1 (en) * 1994-08-25 1996-03-14 Hoechst Ag Combination preparation containing cyclosporin A or FK506 and a xanthine derivative
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
JP4486167B2 (en) 1998-02-27 2010-06-23 アスビオファーマ株式会社 Preventive or therapeutic agent for drug-induced renal injury
SE0000234D0 (en) * 2000-01-26 2000-01-26 Kjell Grankvist Antifungal drug composition and drug delivery system
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
IN2012DN01642A (en) 2009-09-02 2015-06-05 Concert Pharmaceuticals Inc
US20130324564A1 (en) 2010-09-01 2013-12-05 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
KR20150002779A (en) 2012-04-13 2015-01-07 콘서트 파마슈티컬즈, 인크. Substituted xanthine derivatives
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344586A2 (en) * 1988-05-27 1989-12-06 Taiho Pharmaceutical Co., Ltd. Medicine containing a TNF inhibitor
EP0414175A2 (en) * 1989-08-22 1991-02-27 Hoechst Aktiengesellschaft Use of xanthine derivatives to reduce nephrotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344586A2 (en) * 1988-05-27 1989-12-06 Taiho Pharmaceutical Co., Ltd. Medicine containing a TNF inhibitor
EP0414175A2 (en) * 1989-08-22 1991-02-27 Hoechst Aktiengesellschaft Use of xanthine derivatives to reduce nephrotoxicity

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy, vol. 34, no. 2, February 1990, American Society for Microbiology, K.M. WASAN et al.: "Pentoxifylline in amphotericin B toxicity rat model", pages 241-244, see the whole article *
Chemical Abstracts, vol. 92, no. 19, 12 May 1980, (Columbus, Ohio, US), A.J. KOSTAKIS et al.: "The effect of pentoxifylline on rejection of rat cardiac allografts", see page 46, abstract no. 157772a, & IRCS MED. SCI.: LIBR. COMPEND. 1980, 81(1), 15, see the entire document *
Chemical Abstracts, vol. 96, no. 13, 29 March 1982, (Columbus, Ohio, US), V.L. KIRPATOVSKII et al.: "Pharmacological protection of the kidneys from ischemic injury. Mechanism for the realization of antiischemic protection of donor kidneys with preparations from various pharmacological groups", see page 91, abstract no. 97660h, & VESTN. AKAD. MED. NAUK. SSSR 1982, (1), 73-8, see the entire document *
Chemical Abstracts, vol. 96, no. 17, 26 April 1982, (Columbus, Ohio, US), A.J. KOSTAKIS et al.: "Prolongation of cardiac and renal allograft survival by pentoxifylline in rats", see page 55, abstract no. 135560k, & IRCS MED. SCI.: LIBR. COMPEND. 1982, 10(1), 77-8, see the entire document *
Chemical Abstracts, vol. 98, no. 1, 3 January 1983, (Columbus, Ohio, US), V.L. KIRPATOVSKII et al.: "Pharmacological protection of the kidneys from ischemic damage. Efficacy of antiischemic protection of the kidneys in simulated terminal state of the donors", see page 32, abstract no. 304a, & VESTN. AKAD. MED. NAUK. SSSR 1982, (9), 89-92, see the entire document *
Clinical Pharmcology & Therapeutics, vol. 47, no. 2, February 1990, K.L. BERENS et al.: "Effect of pentoxifylline (PTX) on dose-dependent cisplatin (C) nephrotoxicity", page 201, see the whole article *
Comprehensive Therapy, vol. 15, no. 5, 1989, G.P. STELLIN et al.: "Current and potential therapeutic effects of pentoxifylline", pages 11-13, see page 13 *
J. Infect. Dis., vol. 162, no. 1, July 1990, The University of Chicago, D.R. LUKE et al.: "Enhancement of the treatment of experimental candidiasis with vascular decongestants", pages 211-214, see the whole article *
Renal Failure, vol. 11, nos. 2,3, 1989, Marcel Dekker, Inc., L.J. BRUNNER et al.: "Prevention of cyclosporine-induced nephrotoxicity with pentoxitylline", pages 97-104, see the whole article *

Also Published As

Publication number Publication date
AU9084991A (en) 1992-05-26
WO1992007566A2 (en) 1992-05-14

Similar Documents

Publication Publication Date Title
WO1992007566A3 (en) Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
Tamura et al. Phase I study of paclitaxel by three‐hour infusion: hypotension just after infusion is one of the major dose‐limiting toxicities
EP2295063A3 (en) Compositions and the use thereof the treatment of mitochondrial diseases
NZ535616A (en) Indolymaleimide derivatives as protein kinase c inhibitors
KR910019618A (en) Pharmaceutical composition for treating erectile dysfunction
WO1997033608A3 (en) Antagonism of endothelin actions
DK1212060T3 (en) Use of nicotine or its derivatives and L-DOPA in a drug for the treatment of neurological disorders, especially Parkinson's disease
EP0239716A2 (en) Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
WO2001019375A1 (en) Inhibiting t-cell proliferation
PT1027053E (en) METHOD OF PREVENTION OF NEFROTOXICITY CAUSED BY CYCLOSPORINS AND TACROLIMUS
EP0081882B1 (en) Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation
EP0213676B1 (en) Pharmaceutical compositions containing acth (1-24) for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
WO2000071109A3 (en) Pharmaceutical compositions comprising s-(+) -desmethylselegiline for the treatment of withdrawal
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
Korolenko et al. Macrophage stimulation and antitumor effect of Ukrain
KR890701112A (en) Method for treating and treating hepatitis virus infectious disease using 1- (2'-deoxy-2'-fluoro-beta-D-arabino-furanosyl) -5-ethyluracil
Chen et al. Protective effects of Angelica sinensis injection on myocardial ischemia/reperfusion injury in rabbits
Eriksson et al. Effect of naloxone on the hypotensive action of clonidine in the conscious, normotensive goat
US4794104A (en) Pharmaceutical compositions containing ACTH fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
RU2001134896A (en) APPLICATION OF 15-DEOXYSPERGUVALINE FOR TREATMENT OF HYPER REACTIVE INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
Kato et al. Antihypertensive Activity of Orally Administered Methyl O-(4-Hydroxy-3-Methoxycinnamoyl) Reserpate (CD-3400) in Conscious Hypertensive Rats
Marzo et al. Pharmacokinetics of N-[5-(hypoxanthin-9-YL) pentyloxycarbonyl]-L-arginine (ST 789) in the rat and in the mouse
Rouan et al. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients
PH26996A (en) Use of PAF-antagonists for treating autoimmune diseases
Sinet et al. Efficacy of short term continuous Zidovudine infusion at early stages of retroviral infection in mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA